StartEngine
able to raise under the larger Regulation A+ exemption (up to $75 million) in addition to Reg CF, has hosted campaigns for Eliaz Therapeutics and Frontier Bio, a developer of lab-grown human tissue models and tissue-engineered vascular grafts intended as safer preclinical alternatives to animal studies.
- Country
- United States
reg-a-plus
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Crowdfunding & retail investment in biotech | finance-investment | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.